Trial · NCT03164616
Results by group133
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 133
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival (PFS); D + SoC Compared With SoC Alone | D + SoC | 5.5 | 95% Confidence Interval 4.7 to 6.5 | months | |
| Progression-Free Survival (PFS); D + SoC Compared With SoC Alone | SoC Alone | 4.8 | 95% Confidence Interval 4.6 to 5.8 | months | |
| Overall Survival (OS); D + SoC Compared With SoC Alone | D + SoC | 13.3 | 95% Confidence Interval 11.4 to 14.7 | months | |
| Overall Survival (OS); D + SoC Compared With SoC Alone | SoC Alone | 11.7 | 95% Confidence Interval 10.5 to 13.1 | months | |
| PFS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC | T + D + SoC | 6.2 | 95% Confidence Interval 5.0 to 6.5 | months | |
| PFS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC | D + SoC | 5.5 | 95% Confidence Interval 4.7 to 6.5 | months | |
| PFS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC | SoC Alone | 4.8 | 95% Confidence Interval 4.6 to 5.8 | months | |
| OS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC | T + D + SoC | 14.0 | 95% Confidence Interval 11.7 to 16.1 | months | |
| OS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC | D + SoC | 13.3 | 95% Confidence Interval 11.4 to 14.7 | months | |
| OS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC | SoC Alone | 11.7 | 95% Confidence Interval 10.5 to 13.1 | months | |
| Objective Response Rate (ORR) | T + D + SoC | 46.3 | percentage of patients | ||
| Objective Response Rate (ORR) | D + SoC | 48.5 | percentage of patients | ||
| Objective Response Rate (ORR) | SoC Alone | 33.4 | percentage of patients | ||
| Best Objective Response (BoR) | T + D + SoC | CR | 2 | Participants | |
| Best Objective Response (BoR) | D + SoC | CR | 3 | Participants | |
| Best Objective Response (BoR) | SoC Alone | CR | 0 | Participants | |
| Best Objective Response (BoR) | T + D + SoC | PR | 153 | Participants | |
| Best Objective Response (BoR) | D + SoC | PR | 157 | Participants | |
| Best Objective Response (BoR) | SoC Alone | PR | 111 | Participants | |
| Best Objective Response (BoR) | T + D + SoC | SD ≥6 weeks | 120 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03164616/results